Table 2.

Adverse events summary

Event –n (%) (patients)	60 mg SC (single dose) (n = 6)	180 mg SC (single dose) (n = 6)	180 mg Q4W (3 doses) (n = 6)	Total (n = 18)
All AE	6 (100)	6 (100)	6 (100)	6 (100)
Serious AE	0 (0)	2 (33) †	0 (0)	2 (11)
Treatment‐related AE	3 (50)	3 (50)	3 (50)	9 (50)
Serious treatment‐related AE	0 (0)	1 (16.7) ‡	0 (0)	1 (5.6)
Deaths on study	0 (0)	0 (0)	0 (0)	0 (0)
Adverse events occurring in 2 or more patients
Fatigue	2 (33)	1 (17)	2 (33)	5 (28)
Anorexia	2 (33)	1 (17)	1 (17)	4 (22)
Headache	2 (33)	0 (0)	2 (33)	4 (22)
Malaise	1 (17)	3 (50)	0 (0)	4 (22)
Nausea	1 (17)	2 (33)	1 (17)	4 (22)
Arthralgia	2 (33)	0 (0)	1 (17)	3 (17)
Constipation	1 (17)	1 (17)	1 (17)	3 (17)
Diarrhea	2 (33)	0 (0)	1 (17)	3 (17)
Metastases to bone	1 (17)	1 (17)	1 (17)	3 (17)
Edema	1 (17)	1 (17)	1 (17)	3 (17)
Shoulder pain	1 (17)	1 (17)	1 (17)	3 (17)
Stomatitis	2 (33)	1 (17)	0 (0)	3 (17)
Alopecia	2 (33)	0 (0)	0 (0)	2 (11)
Chest pain	1 (17)	1 (17)	0 (0)	2 (11)
Hot flush	0 (0)	1 (17)	1 (17)	2 (11)
Hypoesthesia	0 (0)	0 (0)	2 (33)	2 (11)
Hypocalcemia	1 (17)	1 (17)	0 (0)	2 (11)
Insomnia	0 (0)	2 (33)	0 (0)	2 (11)
Metastases to liver	0 (0)	1 (17)	1 (17)	2 (11)
Nasopharyngitis	1 (17)	1 (17)	0 (0)	2 (11)
Neutrophil count decreased	2 (33)	0 (0)	0 (0)	2 (11)
Pain in extremity	1 (17)	1 (17)	0 (0)	2 (11)
White blood cell count decreased	2 (33)	0 (0)	0 (0)	2 (11)

^† Includes 1 patient with grade 4 myositis and 1 patient with grade 3 febrile neutropenia.

^‡ Includes 1 patient with grade 4 myositis.

AE, adverse events; SC, subcutaneous.